Real-world safety profile of therapy with ibrutinib or acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
作者信息
Hafer Ramsay, Iadevaia Francesco, Rohan Thomas Z, Duong Teresa, Poluch Maria, Keiffer Gina, Li Michael, Ferber Andres, Laurenti Luca, Khoo Alan S, Porcu Pierluigi
机构信息
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University of Sacred Heart, Rome, Italy.
出版信息
Blood Neoplasia. 2024 Dec 28;2(1):100064. doi: 10.1016/j.bneo.2024.100064. eCollection 2025 Feb.
Abstract
摘要
相似文献
1
Real-world safety profile of therapy with ibrutinib or acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.伊布替尼或阿卡替尼治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的真实世界安全性概况。
Blood Neoplasia. 2024 Dec 28;2(1):100064. doi: 10.1016/j.bneo.2024.100064. eCollection 2025 Feb.
2
Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.采用布鲁顿酪氨酸激酶抑制剂阿卡替尼或伊布替尼治疗的慢性淋巴细胞白血病或小细胞淋巴瘤患者的 3 年心血管和非心血管不良事件：真实世界分析。
Ann Hematol. 2024 Nov;103(11):4613-4620. doi: 10.1007/s00277-024-05921-7. Epub 2024 Aug 17.
3
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.初治慢性淋巴细胞白血病患者开始一线应用伊布替尼或阿卡替尼的治疗时间。
Future Oncol. 2024 Jan;20(1):39-53. doi: 10.2217/fon-2023-0436. Epub 2023 Jul 21.
4
A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases.使用两个美国大型真实世界数据库对接受一线伊布替尼或阿卡拉布替尼治疗的慢性淋巴细胞白血病患者的医疗资源利用情况和成本进行比较。
J Comp Eff Res. 2025 Jun;14(6):e240210. doi: 10.57264/cer-2024-0210. Epub 2025 Apr 22.
5
Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia.布鲁顿酪氨酸激酶抑制剂的选择对医疗保险慢性淋巴细胞白血病患者的费用影响
J Comp Eff Res. 2025 Jun 23:e250035. doi: 10.57264/cer-2025-0035.
6
Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.在慢性淋巴细胞白血病一线治疗中阿卡替尼的疗效比较：系统评价和网络荟萃分析。
Clin Ther. 2020 Oct;42(10):1955-1974.e15. doi: 10.1016/j.clinthera.2020.08.017. Epub 2020 Oct 6.
7
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis. Venetoclax 与 Bruton 酪氨酸激酶抑制剂在慢性淋巴细胞白血病（CLL）一线治疗中的比较：系统评价和网络荟萃分析。
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):216-223. doi: 10.1016/j.clml.2020.10.012. Epub 2020 Oct 29.
8
Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病患者中，单药伊布替尼与阿卡替尼一线治疗依从性的真实世界比较。
Patient Prefer Adherence. 2023 Aug 23;17:2073-2084. doi: 10.2147/PPA.S417180. eCollection 2023.
9
A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network.阿卡拉布替尼与依鲁替尼治疗慢性淋巴细胞白血病相关心血管事件的比较分析：来自全球联合网络的见解
Pharmacol Res Perspect. 2025 Jun;13(3):e70113. doi: 10.1002/prp2.70113.
10
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.真实世界中阿卡替尼与伊布替尼在慢性淋巴细胞白血病患者中的比较疗效。
Blood Adv. 2023 Aug 22;7(16):4291-4301. doi: 10.1182/bloodadvances.2023009739.
本文引用的文献
1
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.初治慢性淋巴细胞白血病患者开始一线应用伊布替尼或阿卡替尼的治疗时间。
Future Oncol. 2024 Jan;20(1):39-53. doi: 10.2217/fon-2023-0436. Epub 2023 Jul 21.
2
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.ELEVATE-RR 试验中，阿卡替尼与伊布替尼治疗复发/难治性慢性淋巴细胞白血病的详细安全性比较。
Blood. 2023 Aug 24;142(8):687-699. doi: 10.1182/blood.2022018818.
3
A global federated real-world data and analytics platform for research.一个用于研究的全球联合真实世界数据与分析平台。
JAMIA Open. 2023 May 13;6(2):ooad035. doi: 10.1093/jamiaopen/ooad035. eCollection 2023 Jul.
4
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.真实世界中阿卡替尼与伊布替尼在慢性淋巴细胞白血病患者中的比较疗效。
Blood Adv. 2023 Aug 22;7(16):4291-4301. doi: 10.1182/bloodadvances.2023009739.
5
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.慢性淋巴细胞白血病的诊断与治疗：综述
JAMA. 2023 Mar 21;329(11):918-932. doi: 10.1001/jama.2023.1946.
6
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.RESONATE-2 研究的 8 年随访结果：伊布替尼一线治疗慢性淋巴细胞白血病患者。
Blood Adv. 2022 Jun 14;6(11):3440-3450. doi: 10.1182/bloodadvances.2021006434.
7
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.ELEVATE-TN研究4年随访结果：阿卡拉布替尼联合或不联合奥妥珠单抗对比奥妥珠单抗加苯丁酸氮芥用于初治慢性淋巴细胞白血病的疗效及安全性
Leukemia. 2022 Apr;36(4):1171-1175. doi: 10.1038/s41375-021-01485-x. Epub 2022 Jan 1.
8
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.阿卡替尼与伊布替尼治疗既往治疗的慢性淋巴细胞白血病：首次随机 III 期试验结果。
J Clin Oncol. 2021 Nov 1;39(31):3441-3452. doi: 10.1200/JCO.21.01210. Epub 2021 Jul 26.
9
Managing toxicities of Bruton tyrosine kinase inhibitors.布鲁顿酪氨酸激酶抑制剂的毒性管理。
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):336-345. doi: 10.1182/hematology.2020000118.
10
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.阿卡替尼单药治疗复发/难治性慢性淋巴细胞白血病患者：更新的 2 期结果。
Blood. 2020 Apr 9;135(15):1204-1213. doi: 10.1182/blood.2018884940.
Zotero 插件